RECRUITING

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery

Official Title

Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement

Quick Facts

Study Start:2024-04-17
Study Completion:2025-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06112353

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 or older
  2. * Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
  1. * Allergy to Rocuronium, Vecuronium, or Sugammadex
  2. * Bowel resection surgery requiring an ostomy
  3. * No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
  4. * No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
  5. * Creatinine Clearance (CrCl) of less than 30
  6. * Pregnancy
  7. * Incapable of providing consent or understanding the research project

Contacts and Locations

Study Contact

Paulette Mensah, BA
CONTACT
714-456-8818
pmensah@hs.uci.edu
Robert R Field, MD
CONTACT
714-506-5703
fieldr@hs.uci.edu

Principal Investigator

Robert R Field, MD
PRINCIPAL_INVESTIGATOR
Associate Clinical Professor

Study Locations (Sites)

UC Irvine Medical Center
Orange, California, 92868
United States

Collaborators and Investigators

Sponsor: University of California, Irvine

  • Robert R Field, MD, PRINCIPAL_INVESTIGATOR, Associate Clinical Professor

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-17
Study Completion Date2025-07-31

Study Record Updates

Study Start Date2024-04-17
Study Completion Date2025-07-31

Terms related to this study

Keywords Provided by Researchers

  • Laparoscopic Bowel Resection
  • Sugammadex
  • Neostigmine
  • Glycopyrrolate
  • GI-2

Additional Relevant MeSH Terms

  • Intestinal Disease